KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $844.6 million.

  • Regeneron Pharmaceuticals' Income from Continuing Operations fell 796.56% to $844.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.5 billion, marking a year-over-year increase of 209.17%. This contributed to the annual value of $4.5 billion for FY2025, which is 209.17% up from last year.
  • According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Income from Continuing Operations is $844.6 million, which was down 796.56% from $1.5 billion recorded in Q3 2025.
  • Regeneron Pharmaceuticals' 5-year Income from Continuing Operations high stood at $3.1 billion for Q2 2021, and its period low was $722.0 million during Q1 2024.
  • Moreover, its 5-year median value for Income from Continuing Operations was $1.1 billion (2021), whereas its average is $1.3 billion.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first soared by 24535.83% in 2021, then tumbled by 7250.31% in 2022.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Income from Continuing Operations stood at $2.2 billion in 2021, then crashed by 46.29% to $1.2 billion in 2022, then fell by 3.13% to $1.2 billion in 2023, then fell by 20.86% to $917.7 million in 2024, then fell by 7.97% to $844.6 million in 2025.
  • Its last three reported values are $844.6 million in Q4 2025, $1.5 billion for Q3 2025, and $1.4 billion during Q2 2025.